title: HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?
authors.affiliation: Vascular Medicine and Metabolism Unit, "Saint Joan" University Hospital, Rovira i Virgili University, Sant Llorenç 21, 43201 Reus, Spain. luis.masana@urv.cat
authors.forename: L
authors.initials: L
authors.lastname: Masana
authors.forename: A
authors.initials: A
authors.lastname: Cabré
authors.forename: N
authors.initials: N
authors.lastname: Plana
mesh_terms: D033963:Adaptor Protein Complex 3 / Q000378:metabolism*; D033966:Adaptor Protein Complex beta Subunits / Q000378:metabolism*; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D000069438:Ezetimibe; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use
chemical_list: C439973:AP3B1 protein, human; D033963:Adaptor Protein Complex 3; D033966:Adaptor Protein Complex beta Subunits; D000924:Anticholesteremic Agents; D001384:Azetidines; D000960:Hypolipidemic Agents; D007211:Indoles; C518174:MK-0524; D009525:Niacin; D019821:Simvastatin; D000069438:Ezetimibe
keywords: Ezetimibe; HPS2-THRIVE; LDL; Niacin